Table 3.
Summary of studies by drug class
| Drug class | # Studies | Industry funding (%) | Gov't funding (%) | Private funding (%) | Second‐use drug (%) | % Studies leading to Phase III |
|---|---|---|---|---|---|---|
| Immunotherapy/Monoclonal Antibodies | 40 | 55.3 | 52.6 | 44.7 | 97.5 | 5.0 (2) |
| Alkylating agents | 38 | 73.3 | 30 | 23.3 | 39.5 | 7.9 (3) |
| Anthracyclines | 13 | 66.7 | 16.7 | 16.7 | 100 | 7.7 (1) |
| Kinase Inhibitors | 52 | 74.5 | 51.0 | 21.6 | 100 | 3.8 (2) |
| Microtubule Inhibitors | 18 | 26.7 | 60 | 20 | 100 | 11.1 (2) |
| Antimetabolites | 28 | 52.2 | 69.6 | 34.8 | 100 | 7.1 (2) |
| Antitumor Antibiotics | 2 | 0 | 100 | 0 | 50 | 0 |
| Topoisomerase inhibitors | 14 | 45.5 | 45.5 | 27.3 | 100 | 0 |
| HDAC inhibitors | 5 | 100 | 60 | 20 | 100 | 0 |
| Other drugs/therapies | 28 | 46.4 | 60.7 | 21.4 | 100 | 0 |